Table 2.

Hazards Ratios (HR) of Relapse, NRM, and Treatment Failure Among Pediatric HSCT Recipients (N=140).

	----------Relapse-----------		------------NRM--------------		------Treatment Failure-----
	*HR (95% CI)	p value	*HR (95% CI)	p value	†HR (95% CI)	p value
CMV Serostatus
D−/R−	3.15 (1.46–6.76)	0.003	2.00 (0.44–9.09)	0.37	2.45 (1.46–4.12)	<0.001
Other	1.00		1.00		1.00
Disease Stage
Early	0.20 (0.09–0.46)	<0.001	0.54 (0.09–3.04)	0.48	0.50 (0.28–0.88)	0.02
Other	1.00		1.00		1.00
Recipient Age
0–7 Years	4.28 (1.90–9.64)	<0.001	0.07 (0.01–0.68)	0.02	1.58 (0.94–2.67)	0.08
8–18 Years	1.00		1.00		1.00
Donor Type, Diagnosis
Unrelated, ALL	0.96 (0.39–2.40)	0.93	38.07 (4.82–300.8)	<0.001	2.51 (1.39–4.52)	0.002
Unrelated, AML/MDS	1.48 (0.58–3.77)	0.41	0.44 (0.02–8.02)	0.58	1.22 (0.56–2.65)	0.62
Sibling, Any Diagnosis	1.00		1.00		1.00
Female-to-Male Graft
Yes	0.37 (0.12–1.14)	0.08	18.12 (4.39–74.84)	<0.0001	‡3.85 (1.20–12.34)	0.02
No	1.00		1.00		1.00
Donor Age
40–55 Years	0.75 (0.25–2.27)	0.61	2.06 (0.38–11.28)	0.40	1.87 (0.99–3.53)	0.05
0–39 Years	1.00		1.00		1.00
Graft Source
Bone Marrow	2.14 (0.93–4.93)	0.07	0.29 (0.05–1.64)	0.16	0.79 (0.48–1.29)	0.35
Peripheral Blood	1.00		1.00		1.00
Year of Transplantation
1997–2002	1.27 (0.58–2.78)	0.55	1.46 (0.41–5.14)	0.56	1.43 (0.87–2.38)	0.16
2003–2007	1.00		1.00		1.00

^*Hazards ratios for relapse and NRM are cumulative-incidence based.[23]

^†Hazards ratios for treatment failure are survival-based.[20]

^‡In the model of treatment failure, female-to-male graft is a time-dependent covariate: the hazards ratio for female-to-male graft refers to the first 50 days only.